Skip to main content
Daniel Mulder PhD Queen's University (2011), MD Queen's University (2015)
 Daniel Mulder
Assistant Professor
Pediatric Gastroenterologist
Contact Info

Dr. Mulder’s CIHR-funded graduate studies focused on the role of antigens in driving GI inflammation. After residency, Daniel joined the pediatric gastroenterology clinical fellowship program at the Hospital for Sick Children where he completed a CIHR-funded postdoctoral fellowship in the laboratory of Dr. Aleixo Muise, researching translational and computational approaches to genomic analysis in the pathogenesis of inflammatory bowel disease.

Research Interests

Dr. Mulder is a pediatric gastroenterologist who studies the effects of the immune system on the gastrointestinal tract. Inflammatory bowel disease (IBD) is a life-long chronic disease that has profound impacts on the gastrointestinal tract. IBD is becoming a major health issue with 1 in 100 Canadians projected to have IBD by 2030. IBD is believed to be caused by dysregulation of the immune system through a variety of disrupted processes. These processes and their connection to disease characteristics are complex and poorly understood. Dr. Mulder’s research program aims to use laboratory-based immunophenotyping techniques to create molecular “fingerprints” of individual IBD patients. This “fingerprint” will allow for a personalized approach to treatment, directly targeting the aberrant pathways. Ultimately, through redefining IBD classification by the underlying molecular processes, Dr. Mulder hopes to improve IBD treatment success rates and improve patient outcomes.

Selected Publications

  1. Wang, L, Aschenbrenner D, Zeng Z, Cao X, …, Mulder DJ, …, Boztug K, Huang Y, Li D, Uhlig HH, Muise AM. Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation 1 in humans and mice. Nat Genet. 2021;53(4):500-510.
  2. Ryusuke N, Warner N, Mulder DJ, Kotlarz D, McGovern KPB, Cho J, Klein K, Snapper SB, Griffiths AM, Iwama I, Muise AM. A Systematic Review of Monogenic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021:S1542-3565(21)00331-1.
  3. Sherlock ME, Zachos M, Issenman RM, Mulder DJ. Clinical and laboratory characteristics are associated with biologic therapy use in pediatric inflammatory bowel disease: a retrospective cohort study. J Can Assoc Gastroenterol. [Published ahead of print Oct 15, 2020].
  4. Mulder DJ, Khalouei S, Warner N, Gonzaga-Jauregui C, Church PC, Walters TD, Ramani AK, Griffiths AM, Cohn I, Muise AM. Utilization of Whole Exome Sequencing Data to Identify Clinically Relevant Pharmacogenomic Variants in Inflammatory Bowel Disease. Clin Transl Gastro. 2020;11(12):e00263.
  5. Putra J, Mulder DJ. Solitary Peutz-Jeghers type hamartomatous polyp in the transverse colon of an adolescent with ulcerative colitis. Dig Liver Dis 2019;S1590-8658(19)30795-9.

Further publications: